Bain Capital Life Sciences

Bain Capital Life Sciences

Bain Capital Life Sciences

$75,000,000 Venture capital (Series C)
PE Hub

Annexon Biosciences takes in $75 mln Series C

$80,000,000 Venture capital (Series D)
PE Hub

ViaCyte nabs $80 mln Series D

MedCity News , Xconomy

CRISPR Therapeutics, ViaCyte partner on diabetes therapies

PE Hub

VC-backed Aptinyx goes public

Stock markets Funding
$60,000,000 Venture capital
FinSMEs , PE Hub

Rapid Micro Biosystems Secures $60M in Equity Financing

$70,000,000 Venture capital (Series B)
PE Hub , Venture Funding News

| Aptinyx lands $70 mln Series B


ViaCyte Raises $10M, Moves to Human Trial with New Diabetes Product

Robotics Health Science
$70,000,000 Post-IPO equity
PE Hub

Dicerna scores $70 mln

Funding Stock markets
$50,000,000 Venture capital (Series C)
Solid Biosciences

Solid Biosciences Raises Up To $50 Million In Series C Financing

$3,900,000 Grant
The San Diego Union-Tribune

CIRM grants ViaCyte $3.9 million for diabetes stem cell therapy

$44,000,000 Venture capital (Series B)

Biopharmaceutical Company Annexon Biosciences Closes $44M Series B Funding

Funding Health Science
$65,000,000 Venture capital (Series A)
biospace , FinSMEs

Naurex Spinout Aptinyx Banks 65 Million Series A to Advance Therapies for Neurological Disorders

Science Funding Health

ViaCyte Reports on Stem Cell Diabetes Trial, Absorbs BetaLogics

Science Health